These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 38698647)

  • 1. Gastric emptying in newly diagnosed, treatment-naïve Han Chinese with type 2 diabetes and the impact of 4-week insulin pump therapy.
    Sun Y; Luo Y; Xiang C; Xie C; Huang W; Sun Z; Jones KL; Horowitz M; Rayner CK; Ma J; Wu T
    Diabetes Obes Metab; 2024 Aug; 26(8):3078-3087. PubMed ID: 38698647
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gastric emptying of a glucose drink is predictive of the glycaemic response to oral glucose and mixed meals, but unrelated to antecedent glycaemic control, in type 2 diabetes.
    Xiang C; Sun Y; Luo Y; Xie C; Huang W; Sun Z; Jones KL; Horowitz M; Rayner CK; Ma J; Wu T
    Nutr Diabetes; 2024 Apr; 14(1):13. PubMed ID: 38589353
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of exogenous glucagon-like peptide-1 on blood pressure, heart rate, gastric emptying, mesenteric blood flow and glycaemic responses to oral glucose in older individuals with normal glucose tolerance or type 2 diabetes.
    Trahair LG; Horowitz M; Stevens JE; Feinle-Bisset C; Standfield S; Piscitelli D; Rayner CK; Deane AM; Jones KL
    Diabetologia; 2015 Aug; 58(8):1769-78. PubMed ID: 26048234
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relationships of Glucose, GLP-1, and Insulin Secretion With Gastric Emptying After a 75-g Glucose Load in Type 2 Diabetes.
    Jalleh RJ; Wu T; Jones KL; Rayner CK; Horowitz M; Marathe CS
    J Clin Endocrinol Metab; 2022 Aug; 107(9):e3850-e3856. PubMed ID: 35608823
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Administration of resveratrol for 5 wk has no effect on glucagon-like peptide 1 secretion, gastric emptying, or glycemic control in type 2 diabetes: a randomized controlled trial.
    Thazhath SS; Wu T; Bound MJ; Checklin HL; Standfield S; Jones KL; Horowitz M; Rayner CK
    Am J Clin Nutr; 2016 Jan; 103(1):66-70. PubMed ID: 26607942
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of intragastric administration of L-tryptophan on the glycaemic response to a nutrient drink in men with type 2 diabetes - impacts on gastric emptying, glucoregulatory hormones and glucose absorption.
    Hajishafiee M; Elovaris RA; Jones KL; Heilbronn LK; Horowitz M; Poppitt SD; Feinle-Bisset C
    Nutr Diabetes; 2021 Jan; 11(1):3. PubMed ID: 33414406
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Xenin-25 delays gastric emptying and reduces postprandial glucose levels in humans with and without type 2 diabetes.
    Chowdhury S; Reeds DN; Crimmins DL; Patterson BW; Laciny E; Wang S; Tran HD; Griest TA; Rometo DA; Dunai J; Wallendorf MJ; Ladenson JH; Polonsky KS; Wice BM
    Am J Physiol Gastrointest Liver Physiol; 2014 Feb; 306(4):G301-9. PubMed ID: 24356886
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastric emptying is slower in women than men with type 2 diabetes and impacts on postprandial glycaemia.
    Xiang C; Sun Y; Luo Y; Xie C; Huang W; Jones KL; Horowitz M; Sun Z; Rayner CK; Ma J; Wu T
    Diabetes Obes Metab; 2024 Aug; 26(8):3119-3127. PubMed ID: 38698649
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mixed meal ingestion diminishes glucose excursion in comparison with glucose ingestion via several adaptive mechanisms in people with and without type 2 diabetes.
    Alsalim W; Tura A; Pacini G; Omar B; Bizzotto R; Mari A; Ahrén B
    Diabetes Obes Metab; 2016 Jan; 18(1):24-33. PubMed ID: 26354383
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antidiabetic actions of endogenous and exogenous GLP-1 in type 1 diabetic patients with and without residual β-cell function.
    Kielgast U; Holst JJ; Madsbad S
    Diabetes; 2011 May; 60(5):1599-607. PubMed ID: 21441444
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Defining the role of GLP-1 in the enteroinsulinar axis in type 2 diabetes using DPP-4 inhibition and GLP-1 receptor blockade.
    Aulinger BA; Bedorf A; Kutscherauer G; de Heer J; Holst JJ; Göke B; Schirra J
    Diabetes; 2014 Mar; 63(3):1079-92. PubMed ID: 24296715
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A whey/guar "preload" improves postprandial glycaemia and glycated haemoglobin levels in type 2 diabetes: A 12-week, single-blind, randomized, placebo-controlled trial.
    Watson LE; Phillips LK; Wu T; Bound MJ; Checklin HL; Grivell J; Jones KL; Clifton PM; Horowitz M; Rayner CK
    Diabetes Obes Metab; 2019 Apr; 21(4):930-938. PubMed ID: 30520216
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative effects of proximal and distal small intestinal administration of metformin on plasma glucose and glucagon-like peptide-1, and gastric emptying after oral glucose, in type 2 diabetes.
    Borg MJ; Bound M; Grivell J; Sun Z; Jones KL; Horowitz M; Rayner CK; Wu T
    Diabetes Obes Metab; 2019 Mar; 21(3):640-647. PubMed ID: 30370686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Magnitude of slowing gastric emptying by glucagon-like peptide-1 receptor agonists determines the amelioration of postprandial glucose excursion in Japanese patients with type 2 diabetes.
    Suganuma Y; Shimizu T; Sato T; Morii T; Fujita H; Harada Sassa M; Yamada Y
    J Diabetes Investig; 2020 Mar; 11(2):389-399. PubMed ID: 31301103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liraglutide as adjunct to insulin treatment in type 1 diabetes does not interfere with glycaemic recovery or gastric emptying rate during hypoglycaemia: A randomized, placebo-controlled, double-blind, parallel-group study.
    Frandsen CS; Dejgaard TF; Andersen HU; Holst JJ; Hartmann B; Thorsteinsson B; Madsbad S
    Diabetes Obes Metab; 2017 Jun; 19(6):773-782. PubMed ID: 27868372
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Randomised comparison of intravenous and subcutaneous routes of glucagon-like peptide-1 administration for lowering plasma glucose in hyperglycaemic subjects with type 2 diabetes.
    Quast DR; Lancaster D; Xie C; Bound MJ; Grivell J; Jones KL; Horowitz M; Meier JJ; Wu T; Rayner CK; Nauck MA
    Diabetes Obes Metab; 2024 Sep; 26(9):3897-3905. PubMed ID: 38951936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of subcutaneous glucagon-like peptide 1 (GLP-1 [7-36 amide]) in patients with NIDDM.
    Nauck MA; Wollschläger D; Werner J; Holst JJ; Orskov C; Creutzfeldt W; Willms B
    Diabetologia; 1996 Dec; 39(12):1546-53. PubMed ID: 8960841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effects of sitagliptin on gastric emptying in healthy humans - a randomised, controlled study.
    Stevens JE; Horowitz M; Deacon CF; Nauck M; Rayner CK; Jones KL
    Aliment Pharmacol Ther; 2012 Aug; 36(4):379-90. PubMed ID: 22738299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study.
    DeFronzo RA; Okerson T; Viswanathan P; Guan X; Holcombe JH; MacConell L
    Curr Med Res Opin; 2008 Oct; 24(10):2943-52. PubMed ID: 18786299
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Normalization of fasting glycaemia by intravenous GLP-1 ([7-36 amide] or [7-37]) in type 2 diabetic patients.
    Nauck MA; Weber I; Bach I; Richter S; Orskov C; Holst JJ; Schmiegel W
    Diabet Med; 1998 Nov; 15(11):937-45. PubMed ID: 9827848
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.